Framingham vs QRISK3 Comparison Tool | Which Heart Risk Score Should You Use — Daily Health Tools
Framingham vs QRISK3
Comparison Tool
Calculate your Framingham 10-year heart disease risk instantly, and understand exactly how it differs from the UK's QRISK3 — with an honest guide to which one applies to you.
| Feature | Framingham | ASCVD / PCE | QRISK3 |
|---|---|---|---|
| Origin | US (1998, updated) | US (2013 ACC/AHA) | UK (2017, BMJ) |
| Population validated on | Framingham, Massachusetts | US pooled cohorts | UK primary care (QResearch) |
| Core variables | Age, gender, cholesterol, HDL, SBP, smoking | Same + race | Same + 15-20 more variables |
| Extra variables | — | Race | CKD, AFib, RA, mental illness, ethnicity, SBP variability, steroid use, more |
| Statin threshold | N/A (older model) | 7.5% (US, ACC/AHA) | 10% (UK, NICE) |
| Typically recommended in | Reference/teaching use | United States | United Kingdom (NHS) |
| Can be calculated here? | ✅ Yes (below) | Partial reference only | ❌ Use official calculator |
Research comparing these models found QRISK3 generally produces higher risk estimates than both Framingham and ASCVD/PCE, often reclassifying people into higher risk categories.
Framingham vs QRISK3: Why Two Different Heart Risk Scores Exist
What Variables Does Each Model Actually Use?
Framingham's core variables are relatively simple: age, gender, total cholesterol, HDL cholesterol, systolic blood pressure (and whether it's medically treated), and smoking status. The US ACC/AHA Pooled Cohort Equations (PCE) — the more modern American successor to Framingham — use these same core factors plus race, reflecting 2013 guideline updates.
QRISK3 goes considerably further, incorporating over 20 variables including chronic kidney disease, atrial fibrillation, rheumatoid arthritis, systemic lupus erythematosus, severe mental illness, migraines, erectile dysfunction, corticosteroid use, atypical antipsychotic use, systolic blood pressure variability (not just a single reading), and a Townsend deprivation score reflecting socioeconomic factors, along with specific ethnicity categories including adjustments for South Asian populations. This is precisely why QRISK3 is considered more comprehensive for UK clinical use — and also exactly why it cannot be reasonably approximated by a simplified public calculator without access to its full underlying statistical model.
Why We Only Calculate Framingham Here (And Not QRISK3)
Being transparent about this matters. Framingham's point-based system was designed from the start to be usable with pen and paper — its coefficients and lookup tables are fully public and have been for decades, which is why we can calculate it accurately above. QRISK3, by contrast, uses a Cox proportional hazards survival model with a complex, population-specific baseline hazard function and interaction terms between variables — this isn't something that can be reliably reconstructed from published summaries without risking a materially inaccurate result. Several third-party sites do attempt to replicate QRISK3, but without access to the original algorithm's full technical specification, there's a genuine risk of producing numbers that don't match the validated NHS tool, which could be actively misleading for a clinical decision like whether to start a statin.
Our approach: calculate Framingham accurately (which we can verify), and send you directly to the official QRISK3 calculator at qrisk.org for a genuinely accurate UK-specific result — the same tool used in NHS Health Checks.
Why QRISK3 Usually Shows a Higher Risk Percentage
Research directly comparing the models — including studies in UK, Indian, and Pakistani healthcare populations — has consistently found that QRISK3 tends to produce higher 10-year risk estimates than both Framingham and the US ASCVD/PCE model, for the same person with identical basic risk factors. This is thought to reflect QRISK3's broader variable set (capturing additional real risk contributors that Framingham simply doesn't ask about) combined with differences in how each model was calibrated against its source population. Interestingly, one study found the original Framingham equation tends to overestimate risk by roughly 5% specifically in UK men compared to their actual outcomes — a reminder that a risk model calibrated on one population doesn't always translate perfectly to another, which is part of why QRISK3 was developed specifically for UK use rather than the UK simply adopting Framingham or ASCVD outright.
Statin Treatment Thresholds: A Real US vs UK Difference
🇺🇸 United States
ACC/AHA guidelines generally recommend considering statin therapy at an ASCVD/PCE risk of 7.5% or higher, with shared decision-making encouraged in the 5-7.5% "borderline" range.
🇬🇧 United Kingdom
NICE guidelines recommend considering statin therapy at a QRISK3 score of 10% or higher — a notably higher threshold than the US approach.
This isn't simply one country being more or less cautious — it reflects different health system priorities, cost-effectiveness thresholds, and population-level analyses balancing statin benefits against side effects and prescribing costs at scale. It's a genuinely useful thing to understand if you've seen risk percentages discussed in international health content and wondered why the "treat at" numbers seem to differ.
Which Score Should You Actually Use?
- Living in the UK, registered with a GP: Use QRISK3 via the official calculator, or ask your GP for your result from your NHS Health Check — it's the validated, guideline-recommended tool for your context
- Living in the US: The ASCVD/PCE calculator (available from the ACC) is what your doctor is most likely using in practice, though Framingham (calculated above) remains a widely referenced educational benchmark
- Living elsewhere, or want a general reference number: Framingham remains the most internationally recognized and widely taught model, making it a reasonable general-purpose starting point, understanding it may not be perfectly calibrated to your specific population
- Have a complex medical history (kidney disease, autoimmune conditions, mental illness, taking certain medications): QRISK3's broader variable set will likely capture your risk more accurately than Framingham, which is another reason UK guidelines specifically moved toward it
No matter which model you reference, remember these are all screening estimates, not diagnoses — the goal is identifying who benefits from a more detailed conversation with a doctor about prevention, not delivering a final verdict on your heart health.
Comments
Post a Comment